Posted by Michael Wonder on 18 Jan 2017
FDA grants fast track designation for aTyr's Resolaris to treat limb girdle muscular dystrophy 2B and removes partial clinical hold for Resolaris
18 January 2017 - First reported fast track designation for LGMD2B treatment.
aTyr Pharma today announced that its product candidate Resolaris was granted fast track designation by the U.S. FDA for the treatment of limb girdle muscular dystrophy 2B (LGMD2B), making it the first known therapeutic candidate for the treatment of LGMD2B to receive the designation.
In addition, the FDA removed its partial clinical hold on a dosing ceiling for Resolaris in clinical trials.
